Close Menu

genetic risk variants

One group pointed out differences between study group characteristics, while the other wondered about the role of patient preference.

The new assay, called the CellMax-DNA Genetic Cancer Risk Test, will complement CellMax Life's planned slate of liquid biopsy assays for early cancer detection.

The results showed overall high concordance between test results and whether patients received chemotherapy, with some relevant exceptions.

Genomed, based in Warsaw, offers sequencing-based diagnostic and research services and brought BGI's noninvasive prenatal NIFTY test in house last year.